Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IRADIMED CORPIRMD · Entity 4896 | Director | June 14, 2019 | June 19, 2019 |
| NATUS MEDICAL INCNTUS · Entity 125256 | Director · President and CEO | April 30, 2021 | May 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IRADIMED CORP
Report date June 14, 2019 · Filed June 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,386 |
Ending reported balance
After 2019-06-14 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-06-14 · Exercise / conversion · Acquired 2,458 · Balance 19,759 F1: Originally a 7,374 restricted stock unit award, 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2017 and 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2018. The vesting of the remaining 2,458 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Row 2 · 2019-06-14 · Exercise / conversion · Acquired 3,690 · Balance 23,449 F2: Originally a 7,380 restricted stock unit award, 3,690 restricted stock units became fully vested and non-forfeitable on December 4, 2018. The vesting of the remaining 3,690 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. Row 3 · 2019-06-14 · Exercise / conversion · Acquired 3,937 · Balance 27,386 F3: Originally a 3,937 restricted stock unit award. The vesting of all 3,937 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board. |
Filing footnotes · ownership attribution and instrument terms
F1: Originally a 7,374 restricted stock unit award, 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2017 and 2,458 restricted stock units became fully vested and non-forfeitable on June 27, 2018. The vesting of the remaining 2,458 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
F2: Originally a 7,380 restricted stock unit award, 3,690 restricted stock units became fully vested and non-forfeitable on December 4, 2018. The vesting of the remaining 3,690 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
F3: Originally a 3,937 restricted stock unit award. The vesting of all 3,937 restricted stock units was accelerated by the Board upon the reporting person's last day of service on the board.
NATUS MEDICAL INC
Report date April 30, 2021 · Filed May 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 191,810 |
Reported balance
After 2021-04-30 transaction · row 1
1 source rowRow 1 · 2021-04-30 · Grant · Acquired 489 · Balance 191,810 F1: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2020 through April 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on April 30, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares purchased pursuant to the Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 1, 2020 through April 30, 2021. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on April 30, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2016 Filed Dec 16, 2016 19:32 UTC | IRADIMED CORP IRMD · Entity 4896 | GrantRestricted Stock Units · Derivative | 8,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-090120 · doc1.xml · derivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,695 Underlying: Common Stock · 8,695 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Iradimed Corporation's common stock. F2 · derivative.exercise_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. F2 · derivative.expiration_date: The reporting person received restricted stock units under Iradimed Corporation's 2014 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 14, 2017. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 9,905 | $0.00 Strike: $13.24 | $0.00 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · derivative · entry 6 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,595 Underlying: Common Stock · 9,905 shares Expires 2019-04-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 16,138 | $41.22 | $665,153.49 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · nonDerivative · entry 4 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,980 F2 · price: 1. This transaction was executed in multiple trades a prices ranging from $40.20428 to $41.85357. The price reflected above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 9,905 | $13.24 | $131,142.20 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · nonDerivative · entry 3 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionNon-qualified Stock Option · Derivative | 4,900 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · derivative · entry 5 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 4,900 shares Expires 2020-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 48 equal monthly installments beginning on the date of grant. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | SaleCommon Stock, $0.001 par value per share | 14,138 | $41.61 | $588,225.63 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · nonDerivative · entry 2 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,213 F1 · price: 1.This transaction was executed in multiple trades a prices ranging from $41.47533 to $41.85357. The price reflected above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 20:45 UTC | NATUS MEDICAL INC BABY · Entity 125256 | Exercise / conversionCommon Stock, $0.001 par value per share | 4,900 | $22.50 | $110,250.00 |
DisclosureSEC source: 0000878526-16-000201 · wf-form4_147752909227175.xml · nonDerivative · entry 1 Kennedy Jonathan · CIK 0001451629 · Director · Sr. VP, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.